Help
Options
Didn't know it?
click below
click below
Knew it?
click below
click below
Don't Know
Remaining cards (0)
Know
retry
shuffle
restart
0:00
Embed Code - If you would like this activity on your web page, copy the script below and paste it into your web page.
Normal Size Small Size show me how
Normal Size Small Size show me how
Z - Pharmacology
First Aid - Pharm 2
| Question | Answer |
|---|---|
| Formula for maintenance dose | Cp * CL / F ;;Cp = target plasma concentration F = bioavailibility |
| In patients with impaired renal or hepatic function, the loading dose decreases, increases or remains unchanged? Maintenance dose? | Loading dose remains unchanged Maintenance dose decreases |
| Rate of elimination is constant (constant amount of drug is eliminated per unit time) - what order elimination? What happens to target plasma concentration? | Zero order elimination Target plasma concentration decreases linearly with time |
| Rate of elimination is proportional to drug concentration (constant fraction of drug eliminated per unit time) - what order elimination? What happens to target plasma concentration? | First order elimination Cp decreases exponentially with time |
| Give examples of drugs with zero order elimination | Ethanol Phenytoin Aspirin (at high or toxic concentration) |
| Phase I metabolism ;products, what happens and how eliminated | (reduction, oxidation, hydrolysis) yields _ slightly polar, water-soluble metabolites (often still active) not yet eliminated |
| What phase of metabolism associated with cytochrome P450 | Phase I |
| What phase of metabolism associated with conjugation | Phase II |
| Phase II metabolism ;products, what happens and how eliminated | acetylation, glucoronidation, sulfation) yields Very polar, inactive metanolites (renally excreted) |
| Geriatric patients lose which phase of metabolism first? | Phase I |
| Is it safe? Pharmacokinetics? - which phase of clinical testing of the drug | Phase I |
| Does it work in patients?- which phase of clinical testing of the drug | Phase II |
| Does it work? Double blind - which phase of clinical testing of the drug | Phase III |
| What happens in phase IV of clinical testing of the drug | Postmarketing surveillance |
| A competitive antagonist shifts agonist curve where? | To the right |
| A noncompetitive antagonist (irreversible) shifts agonist curve where? | Downward |
| Urine pH and drug elimination;;what is trapped | Ionized species get trapped. |
| Urine pH and drug elimination;;Ionized species | Ionized species get trapped. |
| Urine pH and drug elimination;;Weak acids what and Tx | Trapped in basic environments. Treat overdose with bicarbonate. |
| Urine pH and drug elimination;;Weak bases what and Tx | Trapped in acidic environments. Treat overdose with ;ammonium chloride. |
| Urine pH and drug elimination;;Trapped in basic environments. | Weak acids |
| Urine pH and drug elimination;;Trapped in acidic environments. | Weak bases |
| dose response curves and;;different antagonists | A. A competitive antagonist shifts curve to the right, decreasing potency and ↑ EC50.;;B. A noncompetitive antago-;nist shifts the agonist curve downward, decreasing efficacy. |
| dose response curves and;;shifts curve to the right, decreasing potency and ↑ EC50. | competitive antagonist |
| dose response curves and;;shifts the curve downward, decreasing efficacy. | noncompetitive antago-;nist |
| dose response curves and;;in a system with spare receptors | the EC50 is lower than the Kd, indicating that to achieve 50% of maximum effect, < 50% of the receptors must be activated. EC50: dose causing 50% of maximal effect. Kd: concentration ofdrug required to bind 50% of receptor sites. |
| dose response curves and;;different agonists | 1. The partial agonist acts on the same receptor system as the full agonist but has a lower maximal efficacy no matter the dose. ;;A partial agonist;may be more potent (as in the figure), less potent, or equally potent; potency is an independent factor. |
| dose response curves and;;may be more potent (as in the figure), less potent, or equally potent; potency is an independent factor. | A partial agonist |
| Efficacy | maximal EFFECT |
| Potency | amount needed for a given EFFECT |
| amount needed for a given EFFECT | Potency |
| maximal EFFECT | Efficacy |
| Therapeutic index | TILE;;LD50/ED50 |
| pre and postsynaptic nervous system neurotransmitters;;Parasymp | ACh;(nicotinic);;ACh;(muscarinic) |
| pre and postsynaptic nervous system neurotransmitters;;Somatic | only one ;ACh (nicotinic) |
| pre and postsynaptic nervous system neurotransmitters;;Sympathetic | pre = ACh (nicotinic);;Ach (muscarinic)- sweat glands ;;NEα,β - Cardiac and smooth;muscle, gland cells, ;nerve terminals;;D1 - Renal vascular smooth muscle |
| nicotinic receptor mech | ACh ligand gated Na+/K+ channels |
| muscarinic receptor mech | ACh G- protein coupled receptors that act through 2nd messengers |
| ACh ligand gated Na+/K+ channels | nicotinic receptor |
| ACh G- protein coupled receptors that act through 2nd messengers | muscarinic receptor |
| G-protein-linked 2nd messengers ;give G protein and major function;;α1 Receptor | q ;;↑ vascular smooth muscle contraction |
| G-protein-linked 2nd messengers ;give G protein and major function;;α2 Receptor | i ;;↓ sympathetic outflow, ↓ insulin release |
| G-protein-linked 2nd messengers ;give G protein and major function;;β1 Receptor | s ;;↑ heart rate, ↑ contractility, ↑ renin release, ↑ lipolysis, ↑ aqueous ;humor formation |
| G-protein-linked 2nd messengers ;give G protein and major function;;β2 Receptor | s ;;Vasodilation, bronchodilation, ↑ glucagon release |
| G-protein-linked 2nd messengers ;give G protein and major function;;M1 Receptor | q ;;CNS |
| G-protein-linked 2nd messengers ;give G protein and major function;;M2 Receptor | i ;;↓ heart rate |
| G-protein-linked 2nd messengers ;give G protein and major function;;M3 Receptor | q ;;↑ exocrine gland secretions |
| G-protein-linked 2nd messengers ;give G protein and major function;;D1 Receptor | s ;;Relaxes renal vascular smooth muscle |
| G-protein-linked 2nd messengers ;give G protein and major function;;D2 Receptor | i ;;Modulates transmitter release, especially in brain |
| G-protein-linked 2nd messengers ;give G protein and major function;;H1 Receptor | q ;;↑ nasal and bronchial mucus production, contraction of bronchioles,pruritus, and pain |
| G-protein-linked 2nd messengers ;give G protein and major function;;H2 Receptor | s ;;↑ gastric acid secretion |
| G-protein-linked 2nd messengers ;give G protein and major function;;V1 Receptor | q ;;↑ vascular smooth muscle contraction |
| G-protein-linked 2nd messengers ;give G protein and major function;;V2 Receptor | s ;;↑ H2O permeability and reabsorption in the collecting tubules of ;the kidney |
| Given the major function and G-protein class name the receptor;;q ;↑ vascular smooth muscle contraction | α1 |
| Given the major function and G-protein class name the receptor;;i ;↓ sympathetic outflow, ↓ insulin release | α2 |
| Given the major function and G-protein class name the receptor;;s ;↑ heart rate, ↑ contractility, ↑ renin release, ↑ lipolysis, ↑ aqueous ;humor formation | β1 |
| Given the major function and G-protein class name the receptor;;s ;Vasodilation, bronchodilation, ↑ glucagon release | β2 |
| Given the major function and G-protein class name the receptor;;q ;CNS | M1 |
| Given the major function and G-protein class name the receptor;;i;↓ heart rate | M2 |
| Given the major function and G-protein class name the receptor;;q ;↑ exocrine gland secretions | M3 |
| Given the major function and G-protein class name the receptor;;s ;Relaxes renal vascular smooth muscle | D1 |
| Given the major function and G-protein class name the receptor;;i ;Modulates transmitter release, especially in brain | D2 |
| Given the major function and G-protein class name the receptor;;q ;↑ nasal and bronchial mucus production, contraction of bronchioles, | H1 |
| Given the major function and G-protein class name the receptor;;s ;↑ gastric acid secretion | H2 |
| Given the major function and G-protein class name the receptor;;q ;↑ vascular smooth muscle contraction | V1 |
| Given the major function and G-protein class name the receptor;;s ;↑ H2O permeability and reabsorption in the collecting tubules of the kidney | V2 |
| G-protein-linked 2nd messengers ;Receptor G-protein class ;;how to remember which goes with which | α1, α2, β1, β2, M1, M2, M3, D1, D2, H1, H2, V1, V2;;"QISS (kiss) and QIQ (kick) till you're SIQ (sick) of SQS (sex)." |
| G-protein-linked 2nd messengers ;Receptor G-protein class ;;3rd messengers... for Gq | HAVe 1 M&M (H1, α1, V1, M1, M3);;↑ Phospholipase C to IP3 (↑Ca2+) and DAG (Protein Kinase C) |
| G-protein-linked 2nd messengers ;Receptor G-protein class ;;3rd messengers... for Gs | β1, β2, D1 H2, V2 ;;↑ Adenylcyclase (↑ATP to cAMP [ ↑ Protein kinase A]) |
| G-protein-linked 2nd messengers ;Receptor G-protein class ;;3rd messengers for... Gi | MAD 2's (M2, α2, D2);;↓Adenylcyclase (↓ATP to cAMP [ ↑ Protein kinase A]) |
| Release of NE from a sympathetic nerve ending is modulated by;;with mech | by NE itself, acting on presynaptic α2 autoreceptors, and by ACh, ;;angiotensin II, and other substances. |
Created by:
christinapham
Popular USMLE sets